HRAS and hepatocellular carcinoma: Rigosertib is a synthetic benzyl styryl sulfone small molecule inhibitor which has been used in the treatment of monomyelocytic leukemia and due to its activity as a RAS- and PLK1-signaling inhibitor, it was investigated in HCC patients who demonstrate upregulation of PLK1 during tumor development and HRAS expression in advanced HCC.